Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol
- PMID: 15157791
- DOI: 10.1016/j.contraception.2003.12.017
Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol
Abstract
Objectives: Poor cycle control and tolerability can be reasons for irregular pill intake. This study compared the tolerability of two low-dose oral contraceptives and their effect on cycle control.
Methods: In this open, group-comparative, randomized multicenter trial in Germany and the Netherlands, women received either 20 microg ethinylestradiol plus 150 microg desogestrel (20EE/DSG; n = 500) or 20 microg ethinylestradiol plus 100 microg levonorgestrel (20EE/LNG; n = 498) for six treatment cycles. Cycle control, dysmenorrhea and premenstrual syndrome (PMS) were assessed using diary cards. Tolerability was assessed using the self-administered questionnaires Psychological General Well-Being Index (PGWBI) and the Profile of Mood States (POMS). Acne was assessed by objective (acne counts) and subjective (no, moderate, mild, severe) acne scoring of the facial area at baseline and treatment cycles 1, 3 and 6.
Results: A total of 404 (78.1%) and 384 (75.3%) women in the 20EE/DSG and 20EE/LNG groups, respectively, completed the trial. The occurrence rate of irregular bleeding and spotting was statistically significantly higher with 20EE/LNG than with 20EE/DSG (0.18 vs. 0.13; p < 0.05). The mean number of bleeding-spotting days per cycle was statistically significantly higher with 20EE/LNG than with 20EE/DSG (0.63 vs. 0.48; p < 0.05). Early withdrawal bleeding was more frequent with 20EE/LNG (0.15 vs. 0.08; p < 0.005), whereas continued withdrawal bleeding was more frequent with 20EE/DSG (0.32 vs. 0.45; p < 0.001); absence of withdrawal bleeding was comparable (0.06 vs. 0.04, respectively). Thirteen subjects in the 20EE/LNG group and three in the 20EE/DSG group discontinued due to unacceptable bleeding (p < 0.05). Dysmenorrhea and PMS decreased comparably in both groups. There were no differences between groups for the mean total scores of PGWBI or POMS at all time-points. Fewer acne lesions were counted with 20EE/DSG vs. 20EE/LNG after six cycles (p < 0.05). The subjective acne scores supported this finding.
Conclusions: 20EE/DSG provided better cycle control than 20EE/LNG with less treatment discontinuation due to unacceptable bleeding. There were no apparent differences between the two groups regarding tolerability and quality of life. There was less acne with 20EE/DSG.
Copyright 2004 Elsevier Inc.
Similar articles
-
A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.Eur J Contracept Reprod Health Care. 2001 Jun;6(2):108-14. Eur J Contracept Reprod Health Care. 2001. PMID: 11518448 Clinical Trial.
-
Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.Eur J Contracept Reprod Health Care. 2001 Mar;6(1):46-53. Eur J Contracept Reprod Health Care. 2001. PMID: 11334476 Clinical Trial.
-
A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.Contraception. 2004 Apr;69(4):271-8. doi: 10.1016/j.contraception.2003.11.003. Contraception. 2004. PMID: 15033400 Clinical Trial.
-
[Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].Minerva Ginecol. 2007 Aug;59(4):415-25. Minerva Ginecol. 2007. PMID: 17923832 Review. Italian.
-
Lower hormone dosage with improved cycle control.Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 2:25-30; discussion 37-9. Eur J Contracept Reprod Health Care. 2002. PMID: 12659399 Review.
Cited by
-
A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms.Obstet Gynecol Int. 2013;2013:487143. doi: 10.1155/2013/487143. Epub 2013 Feb 20. Obstet Gynecol Int. 2013. PMID: 23577032 Free PMC article.
-
Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles.Lipids Health Dis. 2010 Dec 9;9:141. doi: 10.1186/1476-511X-9-141. Lipids Health Dis. 2010. PMID: 21143923 Free PMC article.
-
Acne vulgaris, probiotics and the gut-brain-skin axis - back to the future?Gut Pathog. 2011 Jan 31;3(1):1. doi: 10.1186/1757-4749-3-1. Gut Pathog. 2011. PMID: 21281494 Free PMC article.
-
Identifying the Impacts of Acne and the Use of Questionnaires to Detect These Impacts: A Systematic Literature Review.Am J Clin Dermatol. 2021 Mar;22(2):159-171. doi: 10.1007/s40257-020-00564-6. Am J Clin Dermatol. 2021. PMID: 33175359
-
Combined oral contraceptive pill for primary dysmenorrhoea.Cochrane Database Syst Rev. 2023 Jul 31;7(7):CD002120. doi: 10.1002/14651858.CD002120.pub4. Cochrane Database Syst Rev. 2023. PMID: 37523477 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical